 Low-dose enoximone subjects cardiac transplantation Clinical results effects beta-adrenergic receptors period phosphodiesterase inhibitor positive inotropic vasodilator properties pretransplantation patients end-stage heart failure clinical requirement additional inotropic support clinical course myocardial beta-adrenergic receptor status explanted hearts patients results pretransplantation patients additional inotropic support patients required cessation enoximone adverse effects exacerbation ventricular arrhythmias Sixty-six enoximone-treated patients underwent cardiac transplantation mean days days enoximone whereas patients cardiac transplantation respective pretransplantation survival rates patients enoximone time list transplantation control patients enoximone significant patients enoximone ventricular myocardial beta-adrenergic receptors time transplantation values ventricles pretransplantation patients ventricular myocardium patients enoximone intravenous beta-adrenergic agonists total beta-adrenergic receptor density patients enoximone enoximone intravenous beta-adrenergic agonists patients intravenous beta-adrenergic agonists patients enoximone myocardial beta receptor densities respective subgroups intravenous beta-adrenergic agonists isoproterenol- calcium-mediated contractile responses isolated right ventricular preparations patients enoximone similar values control patients intravenous beta-adrenergic agonists enoximone-related beta-adrenergic subsensitivity damage contractile apparatus